Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
$18.07
-1.0%
$17.23
$12.07
$19.03
$12.67B1.593.44 million shs3.15 million shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$8.09
-2.1%
$8.82
$2.80
$8.97
$291.71M0.6337,931 shs534,599 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
+1.11%+5.13%+6.35%+13.78%+39.31%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
+0.61%-8.83%-9.53%+29.47%+26.49%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
2.1758 of 5 stars
2.30.01.70.03.30.81.9
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
2.55
Moderate Buy$18.964.92% Upside
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest SCLP, IXI, PAA, SBTX, and PIQ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$18.00 ➝ $22.00
4/12/2024
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $22.00
4/12/2024
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$14.50 ➝ $16.00
4/8/2024
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$23.00
3/19/2024
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $23.00
3/1/2024
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$16.50 ➝ $17.50
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
$48.71B0.26$3.28 per share5.51$16.31 per share1.11
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
$1.23B$1.3913.0014.12N/A2.39%10.48%4.33%5/3/2024 (Confirmed)
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/A-29.62%-28.20%N/A

Latest SCLP, IXI, PAA, SBTX, and PIQ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/3/2024N/A
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
$0.37N/A-$0.37N/AN/AN/A  
2/9/202412/31/2023
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
$0.36$0.42+$0.06$0.49$14.30 billion$12.70 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
$1.277.03%+5.94%91.37%3 Years
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A

Latest SCLP, IXI, PAA, SBTX, and PIQ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/4/2024
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
quarterly$0.31756.7%4/30/20245/1/20245/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
0.64
0.98
0.87
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
41.78%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
0.85%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Plains All American Pipeline, L.P. stock logo
PAA
Plains All American Pipeline
4,200701.07 million695.11 millionOptionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

SCLP, IXI, PAA, SBTX, and PIQ Headlines

SourceHeadline
Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2.8%Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2.8%
americanbankingnews.com - April 25 at 1:48 AM
Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2%Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2%
marketbeat.com - April 3 at 2:15 AM
ARS Pharmaceuticals Inc (SPRY)ARS Pharmaceuticals Inc (SPRY)
uk.investing.com - May 11 at 1:32 PM
Wild IslesWild Isles
wwf.org.uk - March 12 at 9:31 AM
A look back at RNA Therapeutics – day oneA look back at RNA Therapeutics – day one
pharmaphorum.com - February 24 at 12:35 AM
SPRY ARS Pharmaceuticals, Inc.SPRY ARS Pharmaceuticals, Inc.
seekingalpha.com - January 24 at 8:04 PM
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger
247wallst.com - November 22 at 6:29 AM
Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsDr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics
nasdaq.com - November 18 at 8:19 PM
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
finance.yahoo.com - November 10 at 6:41 PM
ARS Pharmaceuticals Closes Merger with Silverback TherapeuticsARS Pharmaceuticals Closes Merger with Silverback Therapeutics
finance.yahoo.com - November 8 at 5:59 PM
Silverback : FDA Accepts ARS Pharms NDA For Neffy For Treatment Of Allergic ReactionsSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions
markets.businessinsider.com - October 28 at 8:15 AM
FDA accepts ARS Pharma’s NDA for NeffyFDA accepts ARS Pharma’s NDA for Neffy
thepharmaletter.com - October 24 at 10:29 AM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERISHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI
kentuckytoday.com - October 23 at 7:22 PM
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
finance.yahoo.com - October 21 at 7:59 AM
Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?
aaii.com - October 19 at 11:52 AM
SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNSHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN
bakersfield.com - October 12 at 11:07 PM
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
markets.businessinsider.com - September 17 at 5:10 AM
SBTX Silverback Therapeutics, Inc.SBTX Silverback Therapeutics, Inc.
seekingalpha.com - September 15 at 10:58 PM
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
markets.businessinsider.com - September 6 at 11:53 AM
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
markets.businessinsider.com - August 23 at 6:32 PM
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTX
apnews.com - August 17 at 12:02 PM
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTXSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTX
apnews.com - August 11 at 1:33 AM
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing InvestigationsSHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations
morningstar.com - July 30 at 7:00 AM
INVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYINVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
apnews.com - July 28 at 2:21 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Plains All American Pipeline logo

Plains All American Pipeline

NYSE:PAA
Plains All American Pipeline, L.P., through its subsidiaries, engages in the pipeline transportation, terminaling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates through two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and on barges or railcars. This segment provides terminaling, storage, and other facilities-related services, as well as merchant activities. The NGL segment is involved in natural gas processing and NGL fractionation, storage, transportation, and terminaling. This segment also includes ethane, propane, normal butane, iso-butane, and natural gasoline derived from natural gas production and processing activities, as well as crude oil refining processes. Its NGL components are used for various applications, such as heating, engine, and industrial fuels. The company was founded in 1981 and is headquartered in Houston, Texas. Plains All American Pipeline, L.P. operates as a subsidiary of Plains GP Holdings, L.P.
Silverback Therapeutics logo

Silverback Therapeutics

NASDAQ:SBTX
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.